Summit X LLC’s ImmunityBio IBRX Stock Holding History

Summit X LLC’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,664	Closed	-$28.2K	–	107
2025 Q2	$28.2K	Buy	+10,664	New	+$28.7K	0.01%	254

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit X LLC's IBRX Position: Q3 2025 in Review

Summit X LLC sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 10,664 shares — an estimated $28.2K sold.

Summit X LLC first reported a position in IBRX in Q2 2025 and held it in 1 quarter. The position peaked at $28.2K in Q2 2025. 262 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

Summit X LLC reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
Summit X LLC sold 10,664 ImmunityBio shares in Q3 2025, an estimated $28.2K.
Summit X LLC first reported a position in ImmunityBio in Q2 2025 and held it in 1 quarter.
Summit X LLC's ImmunityBio position peaked at $28.2K in Q2 2025.
262 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Summit X LLC's 13F filing for Q3 2025.